Reta

Retatrutide is a next-generation weight and metabolic peptide often called a "triple agonist" because it hits three pathways at once — GLP-1, GIP, and glucagon. Most weight-loss peptides only hit one or two. GLP-1 and GIP help control appetite, blood sugar, and insulin response — the same pathways behind Ozempic and Tirzepatide. The glucagon piece is what sets Reta apart: it's studied for its ability to increase energy burn and reduce liver fat, which is why research shows bigger changes in body composition than with dual-agonist peptides. In research protocols it is typically dosed twice weekly — that's a research cadence, not a purchase cadence — and is being studied for weight, blood sugar, blood pressure, and metabolic health endpoints. Sold as a research reference standard for in-vitro laboratory use only. Not a drug, dietary supplement, food, cosmetic, or medical device. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any condition.

For research use only. Not for human or veterinary use. This product must be handled by trained personnel in accordance with institutional biosafety guidelines.